InspireMD announced a 122% year-over-year revenue increase to $3.4 million in Q1 2026, driven by strong demand for its CGuard Prime carotid stent system. The company received FDA approval to start the CGUARDIANS III clinical trial for its next-gen SwitchGuard neuro protection system in TCAR procedures and expects FDA approval for its original CGuard delivery system by Q3 2026. Despite a voluntary recall of the CGuard Prime 135 cm delivery system for technical improvements, InspireMD remains confident in its product enhancements and market growth potential, aiming to expand its addressable market with the upcoming CGuard Prime 80 cm approval in H2 2026.
The global aerospace materials market is projected to grow from $60.38 billion in 2026 to $89.58 billion by 2031, at a CAGR of 8.21%. Growth is fueled by rising demand for lightweight composite materials that improve fuel efficiency, increased satell...
State Street Global Advisors & Affiliates disclosed a sale of 1,250 ordinary shares of DCC plc on May 22, 2026, at a price of €61.55 per share. Following this transaction, their total holding in DCC plc stands at 1,189,951 shares, representing 1.3929...
NevGold Corp. reported that all 17 drillholes at its Limousine Butte project in Nevada returned consistent oxide antimony and gold mineralization, with notable grades such as 0.32% antimony over 14.9 meters. This brownfield site contains historic cru...
AutoZone is preparing to release its quarterly earnings report on May 26, 2026, with high expectations for strong performance. Analysts project an earnings per share (EPS) of $36.22 and revenues of $4.86 billion, driven by seasonal demand for automot...
Canada's proposed Bill C-22 faces strong opposition from global tech leaders and privacy advocates who warn it threatens the country's digital economy by undermining data privacy and encryption. Key companies like Meta, Apple, and Signal argue the la...
